Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients
Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
This is a prospective, national, randomized, multicenter, parallel group, Phase III study
that evaluates the effects of AI201901 in Allergic Rhinitis patients, where they will spray
twice a day against azelastine into both nostrils during a 28-day follow-up period.
Phase:
Phase 3
Details
Lead Sponsor:
Abdi Ibrahim Ilac San. ve Tic A.S.
Collaborators:
Ankara City Hospital Bilkent Antalya Training and Research Hospital Diskapi Yildirim Beyazit Education and Research Hospital Dokuz Eylul University Firat University Istanbul Training and Research Hospital Istanbul University Kahramanmaras Sutcu Imam University Uludag University